Sign up to save your podcasts
Or
Share Dr. Ryan Potts, Ph.D. - VP and Head, Induced Proximity Platform, Amgen - Leading The Next Wave Of Innovation In Drug Discovery, To Modulate Any Target, Every Time
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Dr. Ryan Potts, Ph.D. - VP and Head, Induced Proximity Platform, Amgen - Leading The Next Wave Of Innovation In Drug Discovery, To Modulate Any Target, Every Time
Send us a text
Dr. Ryan Potts, Ph.D. is Vice President and Head, Induced Proximity Platform at Amgen ( https://www.amgen.com/science/research-and-development-strategy/multispecifics-and-other-modalities ) which is focused on novel ways to bring two or more molecules in close proximity to each other to tackle drug targets that are currently considered “undruggable.” He also leads Amgen’s Research & Development Postdoctoral Fellows Program ( https://www.amgen.com/science/scientific-community-initiatives/postdoctoral-fellows ).
Dr. Potts obtained his B.S. in Biology from the University of North Carolina and his Ph.D. in Cell and Molecular Biology from UT Southwestern in 2007. In 2008 he was awarded the Sara and Frank McKnight junior faculty position at UT Southwestern Medical Center. During this time his lab focused on answering a long-standing question in cancer biology regarding the cellular function of cancer-testis antigen (CTAs) proteins. In 2011 he was appointed Assistant Professor in the Departments of Physiology, Pharmacology, and Biochemistry at UT Southwestern Medical Center. His lab’s work defined a function for the enigmatic MAGE gene (Melanoma Antigen Gene) family in protein regulation through ubiquitination.
In 2016 Dr. Potts lab moved to St. Jude Children’s Research Hospital where he was an Associate Member in the Department of Cell and Molecular Biology. There his lab continued to work on CTAs, with a focus on elucidating the biochemical, cellular, physiological and pathological functions of the MAGE gene family.
In 2020 Dr. Potts moved to Amgen, Inc. in Thousand Oaks, California to build a new department called the Induced Proximity Platform (IPP).
Important Episode Link - Amgen Molecular Matchmakers Science Cartoon -
https://wwwext.amgen.com/stories/2020/10/new-video-multispecific-medicines-that-work-as-molecular-matchmakers?_gl=1*1ygduyj*_ga*Mjc5OTk2NDUzLjE3MjI0NTk5Nzc.*_ga_CBMSV0J9VL*MTcyMjQ2MzI0MS4yLjEuMTcyMjQ2MzUyMC4zOC4wLjA.
#Amgen #RyanPotts #InducedProximityPlatform #MultispecificDrugs #UndruggableTargets #MolecularMatchmakers #PROTAC #RNATAC #Proteasome #Lysosome #UbiquitinLigases #Ubiquitination #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research
Support the show
View all episodes
By Ira Pastor
5
22 ratings
Send us a text
Dr. Ryan Potts, Ph.D. is Vice President and Head, Induced Proximity Platform at Amgen ( https://www.amgen.com/science/research-and-development-strategy/multispecifics-and-other-modalities ) which is focused on novel ways to bring two or more molecules in close proximity to each other to tackle drug targets that are currently considered “undruggable.” He also leads Amgen’s Research & Development Postdoctoral Fellows Program ( https://www.amgen.com/science/scientific-community-initiatives/postdoctoral-fellows ).
Dr. Potts obtained his B.S. in Biology from the University of North Carolina and his Ph.D. in Cell and Molecular Biology from UT Southwestern in 2007. In 2008 he was awarded the Sara and Frank McKnight junior faculty position at UT Southwestern Medical Center. During this time his lab focused on answering a long-standing question in cancer biology regarding the cellular function of cancer-testis antigen (CTAs) proteins. In 2011 he was appointed Assistant Professor in the Departments of Physiology, Pharmacology, and Biochemistry at UT Southwestern Medical Center. His lab’s work defined a function for the enigmatic MAGE gene (Melanoma Antigen Gene) family in protein regulation through ubiquitination.
In 2016 Dr. Potts lab moved to St. Jude Children’s Research Hospital where he was an Associate Member in the Department of Cell and Molecular Biology. There his lab continued to work on CTAs, with a focus on elucidating the biochemical, cellular, physiological and pathological functions of the MAGE gene family.
In 2020 Dr. Potts moved to Amgen, Inc. in Thousand Oaks, California to build a new department called the Induced Proximity Platform (IPP).
Important Episode Link - Amgen Molecular Matchmakers Science Cartoon -
https://wwwext.amgen.com/stories/2020/10/new-video-multispecific-medicines-that-work-as-molecular-matchmakers?_gl=1*1ygduyj*_ga*Mjc5OTk2NDUzLjE3MjI0NTk5Nzc.*_ga_CBMSV0J9VL*MTcyMjQ2MzI0MS4yLjEuMTcyMjQ2MzUyMC4zOC4wLjA.
#Amgen #RyanPotts #InducedProximityPlatform #MultispecificDrugs #UndruggableTargets #MolecularMatchmakers #PROTAC #RNATAC #Proteasome #Lysosome #UbiquitinLigases #Ubiquitination #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research
Support the show
More shows like Progress, Potential, and Possibilities Podcast / Show
View all
Radiolab
43,941 Listeners
This American Life
90,844 Listeners
The Joe Rogan Experience
226,206 Listeners
Shawn Ryan Show
42,342 Listeners
Unexplainable
2,202 Listeners